Financial Data and Key Metrics Changes - In Q2 2025, Tarsus Pharmaceuticals achieved record net sales exceeding $100 million, specifically $102.7 million, marking a significant milestone for the company [5][14] - The company dispensed approximately 91,000 bottles to patients, slightly above the guidance of 90,000 bottles [14] - The gross to net discount for Q2 was approximately 45%, with expectations to improve to the low 40s by year-end 2025 [15][17] - Cash and cash equivalents at the end of the quarter were approximately $381 million [15] Business Line Data and Key Metrics Changes - Xtendi, the company's primary product, is primarily a new prescription (NRx) business, with over 30% sequential quarterly revenue growth [8][9] - The direct-to-consumer (DTC) campaign has significantly increased prescription volumes, with unaided awareness of Xtendi tripling since the campaign began [10][11] - The number of prescribers has grown to over 20,000, with a notable increase in weekly prescriptions among the core audience [11][12] Market Data and Key Metrics Changes - The DTC campaign has opened new conversations and changed physician behavior, contributing to a growing prescriber base and increasing patient demand [6][9] - Approximately 25 million people in the U.S. are estimated to have Demodex blepharitis, indicating a substantial market opportunity [6] Company Strategy and Development Direction - The company aims to create and lead new categories in eye care, with a focus on expanding the role of Xtendi and advancing the TPO4 program for ocular rosacea [7][19] - Tarsus is committed to scientific innovation and flawless execution, positioning itself to lead in high-impact underserved diseases [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of Xtendi, with expectations for continued success driven by the DTC campaign and a motivated sales force [15][17] - The company anticipates a steady growth trajectory, with no expectation of a "hockey stick" growth pattern but rather a consistent build in market presence [39][48] Other Important Information - The company plans to initiate a Phase II study for ocular rosacea later in 2025, with preparations already underway [18][84] - Regulatory meetings in Japan are on track for the second half of 2025, and potential European regulatory approval for a preservative-free formulation of Xtendi is expected in 2027 [18] Q&A Session Summary Question: Can you talk about the increase in new prescribers? - The increase in prescribers is primarily from the targeted core audience of 15,000, with no erosion in the earlier prescriber base, and the DTC campaign has opened up a broader prescribing funnel [22][24][26] Question: What are the plans for the gross to net discount in 2026 and beyond? - The expectation is to maintain a steady state in the low 40s for gross to net discount, with ongoing efforts to improve that in the current payer environment [30][31] Question: How do you see the cadence of the launch progressing? - The launch is expected to continue steadily, with a strong foundation for growth and a significant untapped market potential remaining [36][39] Question: What is the impact of the DTC campaign? - The DTC campaign has shown early measurable impact, contributing significantly to prescription volumes and consumer awareness [9][66] Question: Can you provide updates on the ocular rosacea program? - The Phase II study for ocular rosacea is on track to start in 2025, with preparations well underway [83][84]